Cargando…

2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells

Poor tumor response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is a significant challenge for effective treatment of head and neck squamous cell carcinoma (HNSCC). Therefore, strategies that may increase tumor response to EGFR TKIs are warranted in order to improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Sobhakumari, Arya, Orcutt, Kevin P., Love-Homan, Laurie, Kowalski, Christopher E., Parsons, Arlene D., Knudson, C. Michael, Simons, Andrean L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282972/
https://www.ncbi.nlm.nih.gov/pubmed/27178822
http://dx.doi.org/10.3727/096504016X14586627440192
_version_ 1782503425183842304
author Sobhakumari, Arya
Orcutt, Kevin P.
Love-Homan, Laurie
Kowalski, Christopher E.
Parsons, Arlene D.
Knudson, C. Michael
Simons, Andrean L.
author_facet Sobhakumari, Arya
Orcutt, Kevin P.
Love-Homan, Laurie
Kowalski, Christopher E.
Parsons, Arlene D.
Knudson, C. Michael
Simons, Andrean L.
author_sort Sobhakumari, Arya
collection PubMed
description Poor tumor response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is a significant challenge for effective treatment of head and neck squamous cell carcinoma (HNSCC). Therefore, strategies that may increase tumor response to EGFR TKIs are warranted in order to improve HNSCC patient treatment and overall survival. HNSCC tumors are highly glycolytic, and increased EGFR signaling has been found to promote glucose metabolism through various mechanisms. We have previously shown that inhibition of glycolysis with 2-deoxy-d-glucose (2DG) significantly enhanced the antitumor effects of cisplatin and radiation, which are commonly used to treat HNSCC. The goal of the current studies is to determine if 2DG will enhance the antitumor activity of the EGFR TKI erlotinib in HNSCC. Erlotinib transiently suppressed glucose consumption accompanied by alterations in pyruvate kinase M2 (PKM2) expression. 2DG enhanced the cytotoxic effect of erlotinib in vitro but reversed the antitumor effect of erlotinib in vivo. 2DG altered the N-glycosylation status of EGFR and induced the endoplasmic reticulum (ER) stress markers CHOP and BiP in vitro. Additionally, the effects of 2DG + erlotinib on cytotoxicity and ER stress in vitro were reversed by mannose but not glucose or antioxidant enzymes. Lastly, the protective effect of 2DG on erlotinib-induced cytotoxicity in vivo was reversed by chloroquine. Altogether, 2DG suppressed the antitumor efficacy of erlotinib in a HNSCC xenograft mouse model, which may be due to increased cytoprotective autophagy mediated by ER stress activation.
format Online
Article
Text
id pubmed-5282972
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Cognizant Communication Corporation
record_format MEDLINE/PubMed
spelling pubmed-52829722017-01-31 2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells Sobhakumari, Arya Orcutt, Kevin P. Love-Homan, Laurie Kowalski, Christopher E. Parsons, Arlene D. Knudson, C. Michael Simons, Andrean L. Oncol Res Article Poor tumor response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is a significant challenge for effective treatment of head and neck squamous cell carcinoma (HNSCC). Therefore, strategies that may increase tumor response to EGFR TKIs are warranted in order to improve HNSCC patient treatment and overall survival. HNSCC tumors are highly glycolytic, and increased EGFR signaling has been found to promote glucose metabolism through various mechanisms. We have previously shown that inhibition of glycolysis with 2-deoxy-d-glucose (2DG) significantly enhanced the antitumor effects of cisplatin and radiation, which are commonly used to treat HNSCC. The goal of the current studies is to determine if 2DG will enhance the antitumor activity of the EGFR TKI erlotinib in HNSCC. Erlotinib transiently suppressed glucose consumption accompanied by alterations in pyruvate kinase M2 (PKM2) expression. 2DG enhanced the cytotoxic effect of erlotinib in vitro but reversed the antitumor effect of erlotinib in vivo. 2DG altered the N-glycosylation status of EGFR and induced the endoplasmic reticulum (ER) stress markers CHOP and BiP in vitro. Additionally, the effects of 2DG + erlotinib on cytotoxicity and ER stress in vitro were reversed by mannose but not glucose or antioxidant enzymes. Lastly, the protective effect of 2DG on erlotinib-induced cytotoxicity in vivo was reversed by chloroquine. Altogether, 2DG suppressed the antitumor efficacy of erlotinib in a HNSCC xenograft mouse model, which may be due to increased cytoprotective autophagy mediated by ER stress activation. Cognizant Communication Corporation 2016-05-11 /pmc/articles/PMC5282972/ /pubmed/27178822 http://dx.doi.org/10.3727/096504016X14586627440192 Text en Copyright © 2016 Cognizant, LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is licensed under a Creative Commons Attribution-NonCommercial NoDerivatives 4.0 International License.
spellingShingle Article
Sobhakumari, Arya
Orcutt, Kevin P.
Love-Homan, Laurie
Kowalski, Christopher E.
Parsons, Arlene D.
Knudson, C. Michael
Simons, Andrean L.
2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells
title 2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells
title_full 2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells
title_fullStr 2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells
title_full_unstemmed 2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells
title_short 2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells
title_sort 2-deoxy-d-glucose suppresses the in vivo antitumor efficacy of erlotinib in head and neck squamous cell carcinoma cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282972/
https://www.ncbi.nlm.nih.gov/pubmed/27178822
http://dx.doi.org/10.3727/096504016X14586627440192
work_keys_str_mv AT sobhakumariarya 2deoxydglucosesuppressestheinvivoantitumorefficacyoferlotinibinheadandnecksquamouscellcarcinomacells
AT orcuttkevinp 2deoxydglucosesuppressestheinvivoantitumorefficacyoferlotinibinheadandnecksquamouscellcarcinomacells
AT lovehomanlaurie 2deoxydglucosesuppressestheinvivoantitumorefficacyoferlotinibinheadandnecksquamouscellcarcinomacells
AT kowalskichristophere 2deoxydglucosesuppressestheinvivoantitumorefficacyoferlotinibinheadandnecksquamouscellcarcinomacells
AT parsonsarlened 2deoxydglucosesuppressestheinvivoantitumorefficacyoferlotinibinheadandnecksquamouscellcarcinomacells
AT knudsoncmichael 2deoxydglucosesuppressestheinvivoantitumorefficacyoferlotinibinheadandnecksquamouscellcarcinomacells
AT simonsandreanl 2deoxydglucosesuppressestheinvivoantitumorefficacyoferlotinibinheadandnecksquamouscellcarcinomacells